bimagrumab safety
25% Cut In Side Effects For Bimagrumab-Semaglutide Obesity Treatment
The bimagrumab-semaglutide combo cuts moderate-to-severe adverse events by 25% compared with bimagrumab alone, while delivering greater weight loss. This result comes from a 24-week phase-2 trial in adults with obesity, showing a safer and more effective dual therapy. Medical Disclaimer: This article is for informational purposes only and does not